SynthesisFrontiers in oncology2025
Fluid overload-associated large B-cell lymphoma: two case report and review of literature.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fluid overload-associated large B-cell lymphoma (FO-LBCL) is an exceptionally rare lymphoma characterized by predominant involvement of serous body cavities-such as the pleura, peritoneum, and pericardium-in the absence of a solid tumor mass. Its low incidence and nonspecific clinical presentation, which often includes symptoms like dyspnea due to effusion, contribute to diagnostic challenges in early stages. This study aims to address current gaps in the understanding of FO-LBCL by reporting two new cases and reviewing the clinical features, treatment regimens, and outcomes of 57 documented patients. Furthermore, through a detailed analysis of FO-LBCL characteristics, this work discusses relevant differential diagnoses and potential treatment strategies. Methods: A literature search of PubMed and Web of Science was performed using the following search queries: (1) "Fluid overload-associated large B-cell lymphoma" OR "FO-LBC"; (2) "Human herpesvirus 8-unrelated" AND "effusion lymphoma"; (3) "HHV8-unrelated" AND "effusion lymphoma". Results: This study included a total of 57 patients. Fluid accumulation most commonly affected the pleural cavity (84.2%), followed by the pericardial (31.6%) and peritoneal (21.1%) cavities. The predominant clinical manifestation was dyspnea (55.8%). Chemotherapy was the primary treatment modality (56.1%), with the R-CHOP regimen representing the most commonly administered protocol. CD20 expression was the most significant favorable prognostic factor (P = 6×10-7). Other factors associated with improved survival included the absence of CD138 expression (P = 0.0009), age ≥ 65 years (P = 0.0015), LDH ≤ 500 U/L (P = 0.0064), the presence of pleural effusion (P = 0.0099), and CD79a expression (P = 0.0411). Treatment with rituximabcontaining chemotherapy regimens was also a significant favorable factor (P = 0.0036). Conclusions: FO-LBCL often presents with dyspnea caused by fluid effusion. Routine laboratory tests typically show no significant abnormalities, making timely pathological examination essential for a definitive diagnosis. Clinicians should enhance their understanding of FO-LBCL characteristics to improve early diagnostic accuracy. It is crucial to select appropriate treatment strategies based on prognostic factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.